Jim Simons’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-34,400
Closed -$132K 4267
2023
Q2
$132K Buy
34,400
+1,900
+6% +$6.97K ﹤0.01% 3407
2023
Q1
$98K Sell
32,500
-3,894
-11% -$13.5K ﹤0.01% 3497
2022
Q4
$75K Buy
36,394
+4,094
+13% +$12.5K ﹤0.01% 3701
2022
Q3
$112K Buy
32,300
+4,700
+17% +$21.4K ﹤0.01% 3557
2022
Q2
$116K Buy
27,600
+6,685
+32% +$15.8K ﹤0.01% 3809
2022
Q1
$64K Sell
20,915
-29,985
-59% -$115K ﹤0.01% 3871
2021
Q4
$237K Buy
+50,900
New +$350K ﹤0.01% 3446
2021
Q3
Sell
-15,900
Closed -$137K 3963
2021
Q2
$137K Buy
+15,900
New +$140K ﹤0.01% 3321

Other funds holding DBTX

Jim Simons's DBTX Position: Q3 2023 in Review

Jim Simons sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 34,400 shares — an estimated $132K sold.

Jim Simons first reported a position in DBTX in Q2 2021 and held it in 8 quarters. The position peaked at $237K in Q4 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

  • Jim Simons reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Jim Simons sold 34,400 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $132K.
  • Jim Simons first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Jim Simons's Decibel Therapeutics, Inc. Common Stock position peaked at $237K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.